中国抗体-B年度报告2023

目錄 2公司資料3概要4主席報告書7生產基地8管理層討論與分析23董事及管理層31企業管治報告48環境、社會及管治報告87董事會報告113獨立核數師報告117綜合財務報表117綜合損益表118綜合全面收益表119綜合財務狀況表121綜合權益變動表122綜合現金流量表124財務報表附註182釋義 15303305307 George William Hunter CAUTHERLEYDylan Carlo TINKER George William Hunter CAUTHERLEYDylan Carlo TINKER 183171712–1716 Dylan Carlo TINKER www.sinomab.com 3681 概要 COVID-19 SM03 (Suciraslimab)RACD22mAb(GMP)BLASuciraslimabSuciraslimabSS 主席報告書 SM17(FIC)IgG4-κ25IL–25IL–25ADIPFSM17AD6.5SM17AD SM17ISM17INDADIADIb RASuciraslimabBLASuciraslimabSuciraslimab 主席報告書 20 生產基地 19,1631,200 管理層討論與分析 FICNCE SM03 (Suciraslimab)RASLESSMCINHLCD22SuciraslimabRAIIIBLASuciraslimabBLA1012GMPBLA SM17(FIC)IL-25SM17INDFDAI(FIH)FIHSADMAD(LSLV)FIH77SM17INDADINDIADIPF SN1011BTKSN1011SN10114INDSLEMSNMOSD SM06CD22SuciraslimabSuciraslimabSM06 管理層討論與分析 SM03 (Suciraslimab) SM03 (Suciraslimab)(RA)(SLE)(SS)(MCI)(NHL)CD22Suciraslimab 管理層討論與分析 SuciraslimabRAIIIIIISuciraslimab(MTX)(topline data)SuciraslimabRASuciraslimabRAIII530510III79SuciraslimabSuciraslimab BLASuciraslimabBLA1012BLAGMPBLASuciraslimab RASuciraslimabSuciraslimabMCIINDSM03RASM03SLEMCISM03 SM17 SM17(FIC)IgG4-κ(alarmin)25IL-25IISM17IL-252(ILC2s)2T(Th2)IL-17RBTh2IL-4IL-5IL-13IL-25(AD)(IPF)SM17IL-252ADIPF SM17IL-252SM17IgE1--24-(DNFB)SM17Th2Th2IL-25 管理層討論與分析 SM17INDFDAI(FIH)ISADMADPK(LSLV)FIH77SM17 INDADINDI24IADIb ADIPF SM17 SN1011 SN1011BTK(SLE)(MS)(NMOSD)SN1011BTK IIPKSN10114INDSLEMSNMOSDSN1011 SM06 SM06CD22SM06SM03 (Suciraslimab)SM06SM06SM06SM06(SLE)(RA)SM06(CMC) 管理層討論與分析 SM09 SM09CD20(NHL)CD20 Everest Medicines II (HK)LimitedSN1011 4183SN1011 19,1631,200(CNC)GMPBLA 43,15875,000 管理層討論與分析 SM03 (Suciraslimab)SM06SM06 SN1011 SM09SM09 SM18SM32SM17PCTSM03SM06PCTPCT SinoMab 21563.5 SM03 (Suciraslimab) 管理層討論與分析 RASM03 (Suciraslimab)SuciraslimabRABLA(MCI)INDRASM03SM03SM03SLEMCISuciraslimabSuciraslimabSSINDII SM17I(LSLV)77(AD)INDIISM17(PK)SM17ADPD24ADIbSM17IPFIND SM06INDSuciraslimab SM06INDPKPD SM09FDA SM06SM09SM18SM32SM20/SM22 管理層討論與分析 BTSM18SM32SM20/SM22 43,15875,000 (RA) 1,2051,6386.0%20205RARA280833SuciraslimabSuciraslimabSuciraslimab 管理層討論與分析 (AD) ADAD65.7AD81.730%AD6001543Th2IL-25SM17AD 86078.1Th2IL-25 B BBBBB a.CD22 —CD22SM03 (Suciraslimab)SM06Bb.CD20 —CD20SM09Bc.BTK —BTKSN1011B 管理層討論與分析 BTBIPF IL-25IL-17RBSM17IL-25IgG4-κ T B–TT NatureCD22SM03 (Suciraslimab)(MCI)CD22 CD22AASM03 (Suciraslimab)/SM06 SM06SM09 10.744.4D2M39.8 管理層討論與分析 135.4180.4(i)RAIII23.5(ii)18.3 97.682.615.2 12.861.9 203.7345.7142.0(i)100.9(ii)103.9(iii)133.8 管理層討論與分析 391.4268.83.30%4.05%3.30%4.70% 497.9 100%63.5% 23 0.240.2913 323.615.0 29 5% 1.2956,834,71973,181,794 董事及管理層 Humanised Antibody for Breast Cancer Treatment)(U.S. Department of Health andHuman Services)Garden State Cancer Centre 64 30Immunomedics, Inc.ImmunomedicsImmunomedicsEngineering a Unique ConjugationSite on AB Light Chain(A 56 331177 6030 49 41 20000538 103908 董事及管理層 37 38 00566 (University of Southampton)(University ofWarwick)(The Johns Hopkins University) 46 George William Hunter CAUTHERLEY81 Cautherley 00566ApoPharma Inc.TranzymePharma Inc.Ocera Therapeutics Inc. Cautherley5540CEO20Cautherley Cautherley(EdinburghNapier University)(Queens Elizabeth II) 董事及管理層 64 70 30 3552036113612108187GEM6207203818Ka WahConstruction Materials (Hong Kong) LimitedTOM2383 FNIH BiomarkerConsortium Neuroscience Steering CommitteeEuropeanInnovative Medicine Initiative (IMI) on NEWMEDSNeuroforum 董事及管理層 1960019621961696 Dylan Carlo TINKER55 TinkerTinker Tinker25TinkerAsiaTech Capital Advisors Pte LtdTinkerAvistaAdvisory Partners Pte LtdTinkerOCP Asia CapitalTinkerTinkerJardine FlemingJP Morgan 54 26 TinkerTinkerPaul H. Nitze 42 董事及管理層 38 45 CMC 15 17GMP 43 15 57 44 82660 16 45 — 14 企業管治報告 C.2.1 ELITES 企業管治報告 ELITES 企業管治報告 George William Hunter CAUTHERLEYDylan Carlo TINKER —— 3.09D 2330 C.2.1 (i)(ii)(iii)(iv)C.2.1 3.133.13 企業管治報告 ✓ 23 George William Hunter CAUTHERLEYDylan Carlo TINKER 1. 2.3. 企業管治報告 1.2. 企業管治報告 George William Hunter CAUTHERLEYDylan Carlo TINKER (i)(ii)(iii)(iv)(v) 企業管治報告 George William Hunter CAUTHERLEYDylan Carlo TINKER E.1.2(c)(i)E.1.2(i) (i) (ii) (iii) (iv) (v) (vi) 910 Dylan Carlo TINKER 企業管治報告 (i)(ii)(iii)(iv) Dylan Carlo TINKER 企業管治報告 110 A.2.1 企業管治報告 •(i)(ii)(iii)(iv)(v) •(i)(ii)(iii)(iv)(v)(vi)(vii)(viii)•• •—— • •(i)(ii) • • • ESG whistleblower@sinomab.com— 企業管治報告 113116 — 3.2915 6225665685% 6152.5%50 5801,0002.5%50 企業管治報告 15303305307(852) 3426 9433message@sinomab.com 2.07A 1 1.1 20231120231231ESG ESGKPI1 1.2 C2ESG2023 ESG ESG(i)ESG(ii)(iii)ESG3.4 ESG6. 環境、社會及管治報告 ESG 1.3 1.4 www.hkexnews.hkwww.sinomab.comESGmessage@sinomab.com 2 ESGESGESGESGESGESG ESG20233.4ESG ESG ESG2024325 3ESG 3.1ESG ESGESG 3.2ESG ESGESG ESGESGESGESGESGESG ESGESGESGESGESGESGESG 環境、社會及管治報告 3.3 ESG 環境、社會及管治報告 環境、社會及管治報告 3.4 ESG 環境、社會及管治報告 4 4.1 NCE SM03SuciraslimabRACD2